Streetbeat News

CLOV

Clover Health Investments, Corp.

https://www.cloverhealth.com

Industry

Medical - Healthcare Plans

Clover Health Investments, Corp. operates as a medicare advantage insurer in the United States. The company through its Clover Assistant, a software platform that provides preferred provider organization and health maintenance organization health plans for medicare-eligible consumers. It also focuses on non-insurance businesses. Clover Health Investments, Corp. was incorporated in 2014 and is based in Franklin, Tennessee.

Open

3.00

Mkt cap

1.5B

Volume

High

3.08

P/E Ratio

-16.00

52-wk high

4.71

Low

2.99

Div yield

N/A

52-wk low

0.61

Clover Health's stock has dipped 32% after Q3 earnings, presenting a potential buying opportunity. The company is improving its financial performance and has received a 4-star rating upgrade for 2026, which could boost market share and secure more deals.

Portfolio Pulse from

November 18, 2024 | 5:00 pm

Clover Health Investments (CLOV) has seen a significant drop of 26.32% over the past four weeks, making it technically oversold. This suggests a potential exhaustion of selling pressure. Additionally, Wall Street analysts are revising earnings estimates higher, indicating a possible trend reversal for CLOV in the near term.

Portfolio Pulse from

November 15, 2024 | 4:00 pm

Clover Health Investments (CLOV) has experienced a significant decline of 25.82% over the past four weeks. However, the stock is now in oversold territory, and Wall Street analysts are revising earnings estimates higher, suggesting a potential trend reversal.

Portfolio Pulse from

November 14, 2024 | 3:45 pm

Clover Health Investments (CLOV) has formed a hammer chart pattern, suggesting support and potential trend reversal. Upward earnings estimate revisions further support a positive outlook.

Portfolio Pulse from

November 12, 2024 | 4:15 pm

Clover Health's third-quarter 2024 results showed strong performance, beating earnings expectations. However, despite this positive outcome, the stock declined as the company revised its fiscal year 2024 outlook.

Portfolio Pulse from

November 07, 2024 | 5:30 pm

Clover Health Investments, Corp. (CLOV) reported a Q3 loss of $0.02 per share, which was better than the Zacks Consensus Estimate of a $0.03 loss. This is an improvement from the $0.09 loss per share reported a year ago.

Portfolio Pulse from

November 07, 2024 | 12:45 am

Clover Health Investments, Corp. (CLOV) held its Q3 2024 earnings call, discussing financial performance and company updates.

Portfolio Pulse from

November 07, 2024 | 12:00 am

Clover Health's strategic shift towards profitability, marked by the divestiture of its non-insurance segment, has resulted in improved earnings. The launch of the Counterpart Health platform aims to diversify revenue streams, mitigating risks from declining Medicare Advantage memberships. The company maintains a strong balance sheet with no long-term debt.

Portfolio Pulse from

November 06, 2024 | 9:00 am

Jim Cramer expressed his preference for Abbott Laboratories over AbbVie, despite AbbVie's strong performance. UBS raised AbbVie's price target. Oracle's data center business is praised, and Core Scientific is likened to Palantir. Clover Health's Medicare plans received a higher Star rating. GXO Logistics is valued for its new partnership, and Sweetgreen is anticipated to release its Q3 results.

Portfolio Pulse from Avi Kapoor

October 17, 2024 | 12:49 pm

Clover Health Investments Corp (NASDAQ:CLOV) shares rose by 4.6% after the company announced an increase in its PPO Medicare Advantage plans' Star rating to 4 Stars for 2025, impacting payments in 2026. The HMO plan rating also improved to 3.5 Stars, with 95% of members covered by PPO plans. The improvement was driven by high scores in healthcare quality metrics, attributed to Clover Assistant technology.

Portfolio Pulse from Henry Khederian

October 11, 2024 | 4:40 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.